A case of concomitant subcorneal pustular dermatosis and erythema nodosum leprosum in borderline lepromatous leprosy-relapses

Abstract

Subcorneal pustular dermatosis (SPD) is a rare, chronic, and recurrent pustular eruption characterized histopathologically by subcorneal pustules that contain neutrophils. SPD has been clearly reported conjunction with other diseases. Leprosy reactions are acute inflammatory process that immunologically driven on the chronic course of leprosy. Erythema nodosum leprosum (ENL) is a type II of leprosy reaction putatively can initiate SPD lesions. We report one case of concomitant SPD and ENL in borderline lepromatous leprosy-relapses. A 41-year-old man with the history of using multidrug therapy-multibacillary for leprosy presented with painful erythematous nodules on the trunk and extremities, accompanied by pustules on erythematous base on the face, arms, buttocks, and legs. There were thickening of both ulnar nerves with gloves and stocking hypesthesia. The bacterial index was 3+ and morphological index was 20\%. Histopathological examination on the pustule revealed subcorneal pustules with exocytosis of neutrophils which supported the diagnosis of SPD. A possible immunologic mechanism has been suggested in the induction of the occurence both SPD and ENL.

Keywords

Subcorneal pustular dermatosis / Erythema nodosum leprosum

CONFLICTS OF INTEREST DISCLOSURE

The authors declare that there is no conflict of interest.

References

[1] Trautinger F, Honigsmann H. Subcorneal pustular dermatosis. Dalam:Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 8th editions. New York: McGraw-Hill; 2012. 383-3855p.

[2] Ahmad K, Ramsay B. Pyoderma gangrenosum associated with subcorneal pustular dermatosis and IgA myeloma. Clin Exp Dermatol. 2008; 34: 46-48. PMid:18627386. http://dx.doi.org/10.1111/j.1365-2230.2008.02886

[3] Saulsbury FT, Kesler RW. Subcorneal pustular dermatosis and systemic lupus erythematosus. Int J Dermatol. 1984; 23: 63-64. http://dx.doi.org/10.1111/j.1365-4362.1984.tb05666

[4] Roger H, Thevener JP, Souteyrand P, et al. Subcorneal pustular dermatosis associated with rheumatoid arthritis and raised IgA: simultaneous remission of skin and joint involvements with dapsone treatment. Ann Rheum Dis. 1990; 49: 190-191. PMid:2181947. http://dx.doi.org/10.1136/ard.49.3.190

[5] Pavithran K. Subcorneal pustular dermatosis in type 2 lepra reaction. Int J Lepr Other Mycobact Dis. 1992; 60(1): 89-91. ISSN 0148-916X.

[6] Moschella SL. An update on the diagnosis and treatment of leprosy. J Am Acad Dermatol. 2004; 51: 417-426. PMid:15337986. https://doi.org/10.1016/j.jaad.2003.11.072

[7] Wojnarowska F, Venning VA. Subconeal pustular dermatosis. In: BurnsT, BreathnachS, CoxN, GriffithsC, editors. Rook’stext book of dermatology. 8th editions. UK: Wiley-Blackwell; 2010. 40. 21-22 p.

[8] Cheng S, Edmonds E, Ben-Gashir M, et al. Subcorneal pustular dermatosis: 50 years on. Clin Exp Dermatol. 2008; 33: 229-233. PMid:18355359. http://dx.doi.org/10.1111/j.1365-2230.2008.02706

[9] Kachemoune A, Blyumin ML. Sneddon-Wilkinson disease resistant to dapsone and colchicine successfully controlled with PUVA. Dermatol Online J [Internet]. 2003 May [cited 2015 May 10]; 9(5): 24-27. Available from: http://escholarship.org/uc/item/1vn304vn

[10] Kahawita IP, Lockwood DNJ. Towards understanding the pathology of erythema nodosum leprosum. Trans R Soc Trop Med Hyg. 2008; 102: 329-337. PMid:18313706. http://dx.doi.org/10.1016/j.trstmh.2008.01.004

[11] Sarno EN, Vieira LMM, Nery JA. Serum levels of tumor necrosis factor-α and interleukin-1 β during leprosy reactional states. Clin Exp Immunol. 1991; 84: 103-108. PMid:2015700.

[12] Grob JJ, Mege JL, Capo C, et al. Role of tumor necrosis factor-α in Sneddon-Wilkinson subcorneal pustular dermatosis. A model of neutrophil priming in vivo. J Am Acad Dermatol. 1991; 25: 944-947. https://doi.org/10.1016/0190-9622(91)70290-I

[13] Weedon B. Tissue reaction patterns. In: Weedon B, editor. Skin pathology. 3rd editions. British: Elsevier; 2010. 129-130 p.

[14] Levine SJ. Tumor necrosis factor alpha (TNF-α ) [Internet]. USA: National Institutes of Health; c2015 [cited 2017 Nov 3]. Available from: www.ssnpstudents.com/wp/wp-content/uploads/2015/02/00368.pdf

[15] McDonald PP, Bald A, Cassatella MA. Activation of the NF-κ B pathway by inflammatory stimuli in human neutrophils. Blood [Internet]. 1997 May [cited 2017 November 3]; 9(88): 3241-3433. Available from: http://www.bloodjournal.org/content/89/9/342

[16] Voigtlander C, Luftl M, Schuler G, et al. Infliximab (anti-tumor necrosis factor α antibody. Arch Dermatol. 2001; 137(12): 1571-1574. PMid:11735706. http://www.doi.org/10.1001/archderm.137.12.1571

[17] Sago JG, Hall RP. Dapsone. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 8th editions. New York: McGraw-Hill; 2012. 2721-2726 p.

[18] Kretschmer L, Maul JT, Hofer T, et al. Interruption of Sneddon-Wilkinson subcorneal pustulation with infliximab. Case Rep Dermatol. 2017; 9: 140-144. PMid:28559813. http://www.doi.org/10.1159/000468917

[19] Berk DR, Hurt MA, Mann C, et al. Sneddon-Wilkinson disease treated with etanercept: report of two cases. Clin Exp Dermatol. 2008; 34: 347-351. PMid:18699836. http://dx.doi.org/10.1111/j.1365-2230.2008.02905

[20] Howell SM, Bessinger GT, Altman CE, et al. Rapid response of IgA pemphigus of the subcorneal pustular dermatosis subtype to treatment with adalimumab and mycophenolate mofetil. J Am Acad Dermatol. 2005; 53(3); 541-543. PMid:16112379. http://dx.doi.org/10.1016/j.jaad.2005.02.051

[21] Ramien ML, Wong A, Keystone JS. Severe refactory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept. Clin Infect Dis. PMid:21292656. 2011; 52(5): 133-135. https://doi.org/10.1093/cid/ciq213

[22] Santos JRS, Vendramini DL, da Costa Nery JA, et al. Etanercept in erythema nodosum leprosum. An Bras Dermatol. 2017; 92(4): 575-577. PMid:28954119. http://dx.doi.org/10.1590/abd1806-4841.20175471

[23] Thangaraju P, Durai V, Showkath Ali MK. The role of etanercept in refractory erythema nodosum leprosum. Int J Mycobacteriol. 2016; 5: 368-369. PMid:27847029. http://dx.doi.org/10.1016/j.ijmyco.2016.07.002

[24] Faber WR, Jensema AJ, Goldschmidt WFM. Treatment of recurrent erythema nodosum leprosum with inflixi3mab. N Eng J Med. 2006; 355: 739. PMid:16914716. http://dx.doi.org/10.1056/NEJMc052955